1.69%
-3.60%
52.53%
63.95%
48.77%
-30.55%
-30.55%
AI Spotlight on IFRX
Company Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States.The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases.It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc.The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017.
InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Market Data
| Last Price | 2.41 |
| Change Percentage | 1.69% |
| Open | 2.38 |
| Previous Close | 2.37 |
| Market Cap ( Millions) | 142 |
| Volume | 259481 |
| Year High | 2.81 |
| Year Low | 1.17 |
| M A 50 | 2.35 |
| M A 200 | 1.72 |
Financial Ratios
| FCF Yield | -33.94% |
| Dividend Yield | 0.00% |
| ROE | -65.54% |
| Debt / Equity | 1.38% |
| Net Debt / EBIDTA | 41.54% |
| Price To Book | 2.12 |
| Price Earnings Ratio | -2.45 |
| Price To FCF | -2.95 |
| Price To sales | 822.54 |
| EV / EBITDA | -1.86 |
News
- Jan -23 - InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
- Jan -16 - InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
- Jan -15 - InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
- Dec -20 - InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
- Nov -15 - InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
- Nov -08 - InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates
- Nov -08 - InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
- Sep -25 - InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
- Sep -24 - 3 Penny Stocks To Buy With Just $750
- Sep -03 - InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
- Aug -27 - InflaRx Announces Participation in September Investor Events
- Aug -08 - InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates
- Aug -08 - InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
- Aug -01 - InflaRx to Report Second Quarter 2024 Results on August 8, 2024
- Jun -24 - InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
- Jun -05 - InflaRx Hosts R&D Event Highlighting the Promise of INF904
- May -21 - InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
- May -08 - InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
- Apr -24 - InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
- Mar -21 - InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Monoclonal Antibodies
Expected Growth : 8.5 %
What the company do ?
Monoclonal Antibodies from InflaRx N.V. are lab-created proteins that mimic natural antibodies to neutralize inflammatory mediators, treating inflammatory diseases.
Why we expect these perspectives ?
Growing demand for targeted therapies, increasing prevalence of inflammatory diseases, and advancements in biotechnology drive the monoclonal antibodies market growth.
Inflarx N.V. Products
| Product Range | What is it ? |
|---|---|
| IFX-1 | A first-in-class monoclonal anti-C5a antibody that targets the complement system, a key component of the innate immune system. |
| IFX-2 | A monoclonal antibody that targets the C5a receptor, a key component of the complement system. |
InflaRx N.V.'s Porter Forces
Threat Of Substitutes
InflaRx N.V. operates in the biotechnology industry, which is characterized by high research and development costs. The threat of substitutes is medium, as there are limited alternatives to the company's products, but the industry is constantly evolving, and new technologies could emerge as substitutes.
Bargaining Power Of Customers
InflaRx N.V. has a diverse customer base, including pharmaceutical companies, research institutions, and hospitals. The bargaining power of customers is low, as they rely on the company's products and services, and there are limited alternative suppliers.
Bargaining Power Of Suppliers
InflaRx N.V. relies on a network of suppliers for raw materials, equipment, and services. The bargaining power of suppliers is medium, as the company has some flexibility in choosing suppliers, but is also dependent on them for critical components.
Threat Of New Entrants
The biotechnology industry is highly competitive, and new entrants can easily disrupt the market. The threat of new entrants is high, as new companies can emerge with innovative technologies and products, posing a threat to InflaRx N.V.'s market share.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. The intensity of rivalry is high, as companies compete for funding, talent, and market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 1.08% |
| Debt Cost | 3.95% |
| Equity Weight | 98.92% |
| Equity Cost | 10.20% |
| WACC | 10.13% |
| Leverage | 1.09% |
InflaRx N.V. : Quality Control
InflaRx N.V. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OXB.L | Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform … |
| AFMD | Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has … |
| SLGL | Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead … |
| MLEC | Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and … |
| EXAI | Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Oxford Biomedica
A-Score
1-Year Total Return ->
🥈
InflaRx
A-Score
1-Year Total Return ->
🥉
Moolec Science
A-Score
1-Year Total Return ->
4
Sol-Gel Technologies
A-Score
1-Year Total Return ->
5
Exscientia
A-Score
1-Year Total Return ->
6
